CorMedix Q3 net revenue $11.5M; net loss narrows to $2.8M; DefenCath access at 60% of US clinics

CorMedix Inc.

2024-Q3 EPS reported -$0.54 revenue$12,262,234

Q3 2024 net revenue of $11.5M from DefenCath first full quarter; net loss $2.8M ($0.05/sh) vs $9.7M loss ($0.17/sh) in Q3 2023.
Commercial agreements now cover ~60% of US outpatient dialysis centers; four of top five dialysis providers.
Cash and short-term investments $46.0M as of Sep 30, 2024; sufficient for at least 12 months.
Operating expenses $14.1M, up 34% YoY due to selling, marketing, G&A for launch.
Clinical study protocol for TPN indication amendment to be submitted to FDA by mid-November; study start H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.